Short answer
Amgen (AMGN) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 and six-month 2026 unaudited results released August 4, 2026; full financial details in Exhibit 99.1.
Amgen 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and six-month 2026 unaudited results released August 4, 2026; full financial details in Exhibit 99.1
- Investor focus on GAAP-to-non-GAAP reconciliation, including EPS, operating margin, expenses and tax rate
- Free cash flow defined as operating cash flow less capital expenditures, providing a liquidity indicator
- Adjustments primarily exclude acquisition-related charges, restructuring costs, investment gains or losses and certain legal items
- Results furnished under Item 2.02, not filed under Section 18 liability provisions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amgen 8-K filings
Get the next AMGN 8-K as it lands
Follow AMGN for push alerts, or ask the research agent what this filing means.